YM022

YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK) -B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively[1]. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo[3].

Product Specifications

CAS Number

[145084-28-2]

UNSPSC

12352005

Hazard Statement

H301

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ym022.html

Purity

99.87

Smiles

O=C(NC1=CC=CC(C)=C1)N[C@H]2C(N(CC(C3=CC=CC=C3C)=O)C4=CC=CC=C4C(C5=CC=CC=C5)=N2)=O

Molecular Formula

C32H28N4O3

Molecular Weight

516.59

Precautions

H301

References & Citations

[1]Nishida A, et al. Pharmacological profile of (R) -1-[2,3-dihydro-1- (2'-methylphenacyl) -2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3- (3-methylphenyl) urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.J Pharmacol Exp Ther. 1994 May;269 (2) :725-31.|[2]Kitano M, et al. Long-lasting cholecystokinin (2) receptor blockade after a single subcutaneous injection of YF476 or YM022.Br J Pharmacol. 2000 Jun;130 (3) :699-705.|[3]Beinborn M, et al. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.Yale J Biol Med. 1998 May-Aug;71 (3-4) :337-46.